Search Results
Dec 15, 2025, 09:05 ET Pivot Bio Announces Additions to Senior Management
development to improve fruit yield. Liberatore completed her Bachelor of Science degree in biology at the University of New Mexico, where she studied DNA damage response and RNA splicing. She also conducted field research at the Lizard Island Research Station in the Great Barrier Reef through the UNM honors
More news about: Pivot Bio, Inc
Dec 15, 2025, 08:03 ET smart #2 Advances Real-World Testing on All-New Electric Compact Architecture
new ECA platform is being validated through rigorous testing.smart #2 will present a new vision while preserving the essential DNA of the fortwo. Progress on-track for world premiere in 2026.HANGZHOU, China,
More news about: smart
Dec 15, 2025, 07:30 ET Pixelgen Technologies Further Expands Asia Presence Through Distribution Agreement with MDxK
innovative technologies for advancing basic science and precision medicine."The Pixelgen Proxiome Kit, Immuno 155, uses the Proximity Network Assay, a DNA-based chemistry where each target and its neighbors in close proximity are assigned a unique spatial position across single cells at an average resolution
More news about: Pixelgen Technologies
Dec 14, 2025, 16:42 ET Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually
IlluminaIllumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in
More news about: MyOme, Inc
Dec 12, 2025, 20:25 ET U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*
component of AKEEGA®, who developed secondary MDS/cancer-therapy-related AML had received previous chemotherapy with platinum agents and/or other DNA-damaging agents, including radiotherapy.For suspected MDS/AML or prolonged hematological toxicities, refer the patient to a hematologist for further
More news about: Johnson & Johnson
Dec 12, 2025, 10:30 ET NanOlogy Unveils Drug Development Program for Rare Pediatric Brainstem Tumor
tumors.The Promise of LSAM-Cisplatin in DIPGIn laboratory research studies, cisplatin has been shown to kill DIPG tumors by binding to DNA and disrupting cell replication, leading to cell death. Unfortunately, current systemically administered cisplatin formulations are associated with numerous
More news about: NanOlogy, LLC
Dec 12, 2025, 10:07 ET Business of Design Week 2025 Concludes
"The original equipment manufacturers (OEMs) of the past were product-focused. The OEM in the future will be a service provider, a system with a strong DNA. Defined with strategy, and then selling services such as mobility, living, insurance and holidays under the umbrella of one brand. If we want to keep
More news about: Business of Design Week (BODW)
Dec 12, 2025, 09:42 ET JETOUR Kicks Off "Middle East Hybrid Night" in Oman, Debuts Three New Models Led by G700
to every journey. Whether it's a family road trips, daily commute, or a weekend off-road adventure, these models adapt seamlessly. True to JETOUR's DNA, they combine proven safety, comfort, and intelligent features into practical yet premium new-energy mobility solutions.The JETOUR HYBRID EVENT
More news about: Jetour
Dec 12, 2025, 09:18 ET AusperBio Announces AHB-137 Monotherapy Achieved 30% Functional Cure Rate in HBe-negative CHB Patients on Stable Nucleos(t)ide Analogue (NA) Therapy
MonotherapyIn patients with baseline HBsAg 100–1,000 IU/mL, 30% of participants achieved functional cure (HBsAg <0.05 IU/mL and HBV DNA<LLOQ) in both 225 mg and 300 mg cohorts. In patients with baseline HBsAg 100–3,000 IU/mL, functional cure was achieved in 13% (225 mg) and 19% (300 mg).
More news about: AusperBio Therapeutics Inc.
Dec 12, 2025, 08:45 ET Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025
and the HER2 therapy trastuzumab- The Actinium-225 alpha-emitter payload of ATNM-400 induced irreversible double-strand DNA breaks and has the potential to produce potent localized tumor killing with reduced off-target lung toxicity that limits the use of antibody drug conjugates
More news about: Actinium Pharmaceuticals, Inc.
Dec 12, 2025, 08:33 ET Sparks Belting and Mol Belting Systems Launch Unified Brand: Sparks Mol
it."Sparks Mol understands that the best customer relationships aren't just transactional; they're built on partnership. That partnership-first DNA remains unchanged—only now it's strengthened by the combined ingenuity, resources, and capabilities of two industry leaders."At Sparks Mol,
More news about: Sparks Mol
Dec 11, 2025, 22:30 ET Movate Acquires Solomo to Strengthen Salesforce and AI Capabilities in Healthcare
balanced "Human + AI" approach. This unique model drives engineering excellence, operational efficiency, and measurable business impact. This innovation DNA and proven expertise have made Movate one of the most awarded and analyst-recognized companies in its revenue range.To know more, visit:
More news about: Movate
Dec 11, 2025, 13:39 ET DNA&STONE CELEBRATES YEAR OF TRANSFORMATION, CREATIVE MOMENTUM, INDUSTRY RECOGNITION AND STRATEGIC TALENT GROWTH
DNA&STONE officially launched in January of 2025 through the merger of two respected Seattle shops: DNA and their strategy-driven, insight-led 26-year legacy with Little Hands of Stone, known for their focus on craft and strong creative spirit."Building DNA&STONE wasn't just
More news about: DNA&STONE
Dec 11, 2025, 10:30 ET Rapafusyn Founder Dr. Jun O. Liu Elected as National Academy of Inventors Fellow
targets, including transcription factors, transmembrane proteins (such as SLCs), and enzymes. The platform has grown to include an industry-leading DNA-Encoded Library (DEL) containing more than 8 billion compounds of non-degrading glues and an early-stage pipeline of potentially first-in-class programs
More news about: Rapafusyn Pharmaceuticals
Dec 11, 2025, 09:29 ET The PHERGuide study demonstrates the utility of circulating tumor DNA for the early detection and real-time monitoring of localized HER2+ breast cancer
results of the PHERGuide study, presented during the 2025 San Antonio Breast Cancer Symposium (SABCS), demonstrate that the presence of circulating tumor DNA (ctDNA) is associated with disease stage.This research paves the way for the use of blood-based ctDNA as a non-invasive tool to determine disease
More news about: MEDSIR
Dec 11, 2025, 09:00 ET Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment
tests involve extraction of all DNA in the blood. A challenge faced by current technologies is that the overwhelming majority of DNA extracted from the blood is not cancer related but in fact "background" DNA. This background DNA interferes in DNA based liquid biopsy tests, especially tests for early-stage
More news about: VolitionRx Limited
Dec 11, 2025, 09:00 ET Kihealth Wins 2025 KidsX Pediatric Innovation People's Choice Award
proactive diagnostics that help families and clinicians act before symptoms begin."Kihealth's proprietary platform detects epigenetic cell-free DNA signals associated with early pancreatic beta-cell loss. By identifying metabolic dysfunction at its earliest stage, often years before traditional tests
More news about: Kihealth
Dec 11, 2025, 09:00 ET Five Leading Cancer Centers Unite to Target CD123 and Eradicate Hidden Leukemia Cells
scientific dataset. Blood and bone marrow samples collected throughout treatment will be analyzed using state-of-the-art approaches such as circulating tumor DNA profiling, single-cell sequencing and immunophenotyping, and advanced proteomic analyses. "Alongside routine clinical tests, we are also developing
More news about: Break Through Cancer
Dec 11, 2025, 08:05 ET TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial
TTX-MC138 in patients who have demonstrated a pathological complete response following standard-of-care therapy but have evidence of circulating tumor DNA (ctDNA) is based on the high degree of recurrence in those patients and the lack of effective therapies in that setting. TTX-MC138 offers a therapeutic
More news about: TransCode Therapeutics, Inc.
Dec 11, 2025, 06:21 ET DNAe Unveils Early Access Program for LiDia‑SEQ™: Hospital Teams Invited to Trial DNAe's Flagship Tests and Preview DNAe's Innovative NGS Diagnostic Platform
diagnostic and treatment pathways for bloodstream infections and the prevention of sepsis. DNAe is also working on a range of tests for circulating tumor DNA in blood.Samuel Reed, CEO of DNAe, comments: "Our Early Access Program launch is a pivotal moment in the evolution of the LiDia‑SEQ™ platform
More news about: DNAe
Dec 11, 2025, 03:40 ET Mysteries of migration
ever discovered in the Fujian area. More importantly, by extracting its DNA, scholars have provided scientific evidence for the origins of the Austronesian peoples.In 2020, an essay in the journal Science, titled Ancient DNA indicates human population shifts and admixture in northern and southern
More news about: China Daily
Dec 11, 2025, 02:32 ET ImpetusDX Introduces IDX Oral Health Microbial Testing Panel to Support More Informed Periodontal Care
ImpetusDX is stepping into that need with the launch of its IDX Oral Health Microbial Testing panel, a rapid, DNA-based saliva test that identifies key oral microorganisms within as little as 24 hours and integrates seamlessly into routine hygiene visits.
More news about: ImpetusDX
Dec 10, 2025, 16:15 ET Harley-Davidson Announces Key Leadership Changes
traded all-electric motorcycle company in the United States. LiveWire is the future in the making for the pursuit of urban adventure and beyond. Drawing on its DNA as an agile disruptor from the lineage of Harley-Davidson and capitalizing on a decade of learnings in the EV sector, LiveWire's ambition is to be the
More news about: Harley-Davidson, Inc.
Dec 10, 2025, 08:33 ET Groundbreaking Ceremony Launches New Modular Interim Housing at Testimonial Community Love Center in South Los Angeles
Hollywood Handy Construction, emphasized the power of collaboration in making this development possible. She recognized the dedication of project partners DNA Architecture + Design, Mandeville Modular Inc., Optimal Construction, and Brilliant Corners, noting that each organization played a crucial role in bringing
More news about: Hollywood Handy Construction
Dec 10, 2025, 01:00 ET Hanwha Life CGO Dong-Won Kim Reaffirms Commitment to Strengthening South Korea-UAE Financial Cooperation at ADFW 2025
the lead in carrying forward a "100-year partnership" between the two nations.Mr. Kim emphasised that South Korea and the UAE "share a common DNA – one that transforms crises into opportunities, embraces change with courage, and values trust-based, long-term partnerships". He added that finance
More news about: Hanwha Life